AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20656163
Drug: Intracameral epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracameral epinephrine (0.2 mL, 1:5000 solution)
Trial: 18635256
Drug: Methotrexate plus
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate plus etanercept 50 mg/week
Trial: 18635256
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate alone (titrated from 7.5 mg to 20 mg/week)
Trial: 15766304
Drug: Levetiracetam (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (500 to 1000 mg titrated to 2000 mg/day, maximum 3000 mg/day)
Trial: 12186343
Drug: Initial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial preparation (IP) including scaling and root planing followed by apically repositioned flap surgery
Trial: 12186343
Drug: Initial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial preparation (IP) only
Trial: 10568044
Drug: Tardyferon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tardyferon (1 tablet per day for two months starting on the 4th day after delivery)
Trial: 10568044
Drug: Tardyferon Fol
RxNorm normalized name: Niva-Fol
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tardyferon Fol (1 tablet per day for two months starting on the 4th day after delivery)
Trial: 7517238
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (Control group)
Trial: 2009366
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg per day cyclosporine A (CyA) from day -1 to day +20 after bone marrow transplant (BMT)
Trial: 2009366
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg per day cyclosporine A (CyA) from day -1 to day +20 after bone marrow transplant (BMT)
Trial: 2009366
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg per day cyclosporine A (CyA)
Trial: 2009366
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg per day cyclosporine A (CyA)
Trial: 7171417
Drug: Pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with tubocurarine
Trial: 24593664
Drug: Topical petroleum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical petroleum jelly (2 g/kg, twice daily until 34 weeks of gestation)
Trial: 24593664
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical petroleum jelly treatment (Control)
Trial: 10475357
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Pygeum africanum extract twice daily
Trial: 10475357
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Pygeum africanum extract once daily
Trial: 31117088
Drug: Enarodustat 2
RxNorm normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Enarodustat 2 mg
Trial: 31117088
Drug: Enarodustat 4
RxNorm normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Enarodustat 4 mg
Trial: 31117088
Drug: Enarodustat 6
RxNorm normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Enarodustat 6 mg
Trial: 31117088
Drug: Enarodustat (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enarodustat (any dose)
Trial: 19158801
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin (10 ml kg(‐1))
Trial: 19158801
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) (10 ml kg(‐1))
Trial: 17680182
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural ropivacaine at 6 mg x h(‐1) (group R‐6)
Trial: 17680182
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural ropivacaine at 18 mg x h(‐1) (group R‐18)
Trial: 17680182
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural ropivacaine at 12 mg x h(‐1)
Trial: 29392749
Drug: Mobile application-based
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application-based treatment for urinary incontinence
Trial: 20443719
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol valerate (2 mg) with or without medroxyprogesterone acetate (5 mg)
Trial: 17355218
Drug: Cisplatin/pemetrexed combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/pemetrexed combination chemotherapy
Trial: 17355218
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy options
Trial: 17355218
Drug: Newest biologically
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newest biologically targeted therapies
Trial: 2260727
Drug: Borage oil
RxNorm normalized name: Borage oil
DrugBank: Borage oil (DB11238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borage oil (4.5 ml/day for 4 weeks)
Trial: 2260727
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4.5 ml/day for 4 weeks)
Trial: 2260727
Drug: Control (safflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (safflower oil, 4.5 ml/day for 4 weeks)
Trial: 27292093
Drug: Biological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological treatments for psoriasis (specifics on dosage and duration not provided)
Trial: 15897799
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma interleukin (IL)-6 and soluble tumor necrosis factor receptor (sTNFR) 1 concentrations
Trial: 15897799
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of selected baseline proinflammatory cytokine concentrations and APACHE II score
Trial: 2540786
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of lisinopril (10 mg)
Trial: 2540786
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of lisinopril (5 mg)
Trial: 345994
Drug: Lynestrenol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lynestrenol (10 mg per day from the 10th to the 24th day of the cycle)
Trial: 23768094
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet (specific details on dosage and duration not available)
Trial: 9381383
Drug: Lovastatin (40-60-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40-60-80 mg daily)
Trial: 9381383
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hypolipidemic therapy)
Trial: 3094207
Drug: Conventional azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional azathioprine and low-dose prednisolone (AP)
Trial: 3094207
Drug: Biopsies several
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biopsies several years after transplantation (AP therapy)
Trial: 30343314
Drug: AR-301 (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-301 (human monoclonal antibody)
Trial: 23334785
Drug: 810-nm continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 810-nm continuous wave low-level laser therapy (LLLT)
Trial: 22183484
Drug: budesonide/formoterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/formoterol combination
Trial: 16365224
Drug: Dornase alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alfa (2.5 mg)
Trial: 16365224
Drug: Hypotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic saline solution (5 mL)
Trial: 9604976
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS), 200 microg twice a day
Trial: 9604976
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray, 200 microg twice a day
Trial: 7699845
Drug: SY5555 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY5555 administered at daily doses between 3.4-10 mg/kg, t.i.d., for 3-14 days
Trial: 2773845
Drug: Iron-folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-folic acid supplements for 60 days
Trial: 411668
Drug: Spironolactone (Aldactone)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (Aldactone) 400 mg/day
Trial: 411668
Drug: Spironolactone (Aldactone)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (Aldactone) 300 mg/day
Trial: 411668
Drug: Spironolactone (Aldactone)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (Aldactone) 200 mg/day
Trial: 411668
Drug: Spironolactone (Aldactone)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (Aldactone) 100 mg/day
Trial: 21967490
Drug: Posaconazole 200mg
RxNorm normalized name: POSACONAZOLE 200MG EC TAB
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 200mg once daily for 24 weeks
Trial: 21967490
Drug: Posaconazole 400mg
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400mg once daily for 24 weeks
Trial: 21967490
Drug: Posaconazole 400mg
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400mg once daily for 12 weeks
Trial: 21967490
Drug: Terbinafine 250mg
RxNorm normalized name: terbinafine 250 MG
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbinafine 250mg once daily for 12 weeks
Trial: 15802774
Drug: Bisphosphonates (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates (first-line drugs)
Trial: 15802774
Drug: Active vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitamin D3 and vitamin K2 (second-line drugs)
Trial: 10320242
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive operation (L-shaped sternotomy)
Trial: 30530975
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg bryostatin
Trial: 30530975
Drug: 40 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg bryostatin
Trial: 25623412
Drug: SBIRT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SBIRT intervention (online Screening, Brief Intervention, and Referral to Treatment)
Trial: 24890141
Drug: KumaFix fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KumaFix fixation system (treatment group, n = 23)
Trial: 22571474
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy (VSL#3), n=31
Trial: 20602781
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg daily
Trial: 20602781
Drug: Pregabalin 450
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 450 mg daily
Trial: 21639874
Drug: Pregabalin 600
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 600 mg daily
Trial: 17613582
Drug: Psychosocial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial intervention (up to 16 meetings over six months, approximately weekly for 12 weeks, followed by tri-weekly sessions for another 12 weeks, lasting approximately 1 hour each)
Trial: 16097635
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor binding in the caudate nucleus and putamen in the PD-JPD group
Trial: 16097635
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor binding in the putamen in the MSA-PSP group
Trial: 16097635
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor binding in the PD-JPD group
Trial: 16097635
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor binding in the MSA-PSP group
Trial: 12033702
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (250 ml, approximately 23 g of ethanol) with the noon meal
Trial: 7576329
Drug: Intervention community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention community (STD treatment)
Trial: 7576329
Drug: Comparison community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison community (no STD treatment)
Trial: 6980774
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tilcotil (Ro 12-0068) daily
Trial: 6980774
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg aspirin 4-times daily
Trial: 29150250
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5mg + Losartan 100mg + Rosuvastatin 20mg (A/L/R 5/100/20)
Trial: 29150250
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5mg + Losartan 100mg (A/L 5/100)
Trial: 29150250
Drug: Losartan 100mg
RxNorm normalized name: LOSARTAN 100MG TAB
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 100mg + Rosuvastatin 20mg (L/R 100/20)
Trial: 24943855
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg 0.5% prilocaine
Trial: 24943855
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg 0.5% prilocaine plus 50 mg dexketoprofen
Trial: 24943855
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg 0.5% prilocaine plus 8 mg dexamethasone
Trial: 10836288
Drug: Citalopram (highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (highly selective serotonin uptake inhibitor)
Trial: 10836288
Drug: TTCAs (adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTCAs (adrenergic tetracyclic antidepressants)
Trial: 9342579
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg valsartan, once-daily for 8 days
Trial: 27921517
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17-OHPC) weekly injections, full compliance (100%)
Trial: 27921517
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17-OHPC) weekly injections, partial compliance (40-80%)
Trial: 17925589
Drug: Tolvaptan 60-240
RxNorm normalized name: tolvaptan 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 60-240 mg (study 1)
Trial: 17925589
Drug: Tolvaptan 180-480
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan 180-480 mg (study 2)
Trial: 11702012
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ribavirin + interferon-alpha)
Trial: 8483846
Drug: Procaterol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol (oral administration)
Trial: 8483846
Drug: Procaterol (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol (tablet administration)
Trial: 3120928
Drug: Oral cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporin (5 mg/kg/day) for 12 weeks
Trial: 27611703
Drug: 2 g/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/kg/week IVIG (Arm A)
Trial: 27611703
Drug: 1 g/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg/week IVIG + 0.5 mg/kg/day prednisone (Arm B)
Trial: 20864862
Drug: High-frequency, low-magnitude
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-frequency, low-magnitude vibration (30 Hz, 0.3 g peak acceleration) for 10 min/day for 6 months
Trial: 20032168
Drug: Exercise prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise prescription
Trial: 14660460
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% monotherapy once daily for 6 months
Trial: 14660460
Drug: Dual ocular
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual ocular hypotensive therapy
Trial: 18703470
Drug: PCI plus
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI plus optimal medical therapy
Trial: 31169029
Drug: Family-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-assisted therapy from a family member trained by a physiotherapist
Trial: 29954931
Drug: Prednisone/sirolimus/calcineurin-inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone/sirolimus/calcineurin-inhibitor
Trial: 20032790
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IIT) - maintenance of blood glucose between 80 mg/dL and 110 mg/dL with continuous insulin infusion
Trial: 20032790
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic therapy (CGT) - maintenance of blood glucose below 180 mg/dL with subcutaneous insulin and insulin infusion if blood glucose levels exceeded 220 mg/dL
Trial: 20032790
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic therapy (CGT)
Trial: 11939911
Drug: Four-drug multimodal
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug multimodal regimen (dexamethasone 4 mg, ondansetron 4 mg, droperidol 1.25 mg, metoclopramide 10 mg i.v.)
Trial: 11939911
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol infusion (1 mg/kg/h during the operation and the first 4 postoperative hours)
Trial: 11939911
Drug: Four-drug multimodal
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug multimodal regimen (M group)
Trial: 11939911
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol infusion (P group)
Trial: 9830641
Drug: Inferior alveolar
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inferior alveolar nerve block + intraosseous injection (0.9 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 9830641
Drug: Inferior alveolar
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inferior alveolar nerve block + mock intraosseous injection
Trial: 1105543
Drug: Fluphenazine 0.5
RxNorm normalized name: fluphenazine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine 0.5 mg/nortriptyline 10 mg three times daily